Cardium’s New Excellagen FDA 510(k) Submission Based on Expanded Structural and Functional Properties

Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional Properties (via PR Newswire)

The Company Also Provides Update on CE Mark Submission Download image Logo. (PRNewsFoto/Cardium Therapeutics) SAN DIEGO, Aug. 5, 2013 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced that it has filed a new 510(k) submission for…